These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 32956756

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
    Rothenberg ME, Roufosse F, Faguer S, Gleich GJ, Steinfeld J, Yancey SW, Mavropoulou E, Kwon N, HES Mepolizumab Study Group.
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2367-2374.e3. PubMed ID: 35568330
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.
    Pane F, Lefevre G, Kwon N, Bentley JH, Yancey SW, Steinfeld J.
    Front Immunol; 2022 Sep; 13():935996. PubMed ID: 36091012
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
    Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD.
    J Allergy Clin Immunol; 2013 Feb; 131(2):461-7.e1-5. PubMed ID: 23040887
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008 Feb; 9(2):125-30. PubMed ID: 18298130
    [Abstract] [Full Text] [Related]

  • 11. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
    Kuang FL, Fay MP, Ware J, Wetzler L, Holland-Thomas N, Brown T, Ortega H, Steinfeld J, Khoury P, Klion AD.
    J Allergy Clin Immunol Pract; 2018 Feb; 6(5):1518-1527.e5. PubMed ID: 29751154
    [Abstract] [Full Text] [Related]

  • 12. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB, Sheikh J, Singh A.
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [Abstract] [Full Text] [Related]

  • 13. Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome.
    Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, Magee T, Piligian B, Yoon P, Ellis JH, Sun X, Panch SR, Powers A, Alao H, Kumar S, Quezado M, Yan L, Lee N, Kolbeck R, Newbold P, Goldman M, Fay MP, Khoury P, Maric I, Klion AD.
    N Engl J Med; 2019 Apr 04; 380(14):1336-1346. PubMed ID: 30943337
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
    Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ, EGPA Mepolizumab Study Team.
    N Engl J Med; 2017 May 18; 376(20):1921-1932. PubMed ID: 28514601
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A.
    Lancet Respir Med; 2017 May 18; 5(5):390-400. PubMed ID: 28395936
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T, Odajima H, Okamasa A, Kawase M, Komatsubara M, Mayer B, Yancey S, Ortega H.
    Allergol Int; 2017 Jul 18; 66(3):445-451. PubMed ID: 28110896
    [Abstract] [Full Text] [Related]

  • 18. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
    Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, Harris SS, Mayer B, Rubin DB, Yancey SW, Sciurba FC.
    N Engl J Med; 2017 Oct 26; 377(17):1613-1629. PubMed ID: 28893134
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome.
    Matucci A, Liotta F, Vivarelli E, Dies L, Annunziato F, Piccinni MP, Nencini F, Pratesi S, Maggi E, Vultaggio A.
    Front Immunol; 2018 Oct 26; 9():1198. PubMed ID: 29896203
    [Abstract] [Full Text] [Related]

  • 20. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
    Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD.
    J Allergy Clin Immunol; 2009 Dec 26; 124(6):1319-25.e3. PubMed ID: 19910029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.